Journal of Biotechnology & Biomaterials
Open Access

Abstract

Glucose metabolism is 200 times higher in cancer affected tissues in comparison to normal tissue as a strategy to support tumor growth and progression, historically known as the â�?�?Warburg effectâ�?�?. Hexokinase is the first enzyme of the glycolytic pathway that catalyzes the phosphorylation of glucose for its activation to glucose-6-phosphate and uses ATP as high-energy source of phosphates. Four isozymes are present in human body with hexokinase 2 (HK2) as most active and specifically expressed in variety of different cancers. However, HK2 binding to the outer mitochondrial membrane not only gives it prime access to ATP generated by the mitochondrial but inhibit apoptosis. Here, we aim to biochemically and structurally characterize interactions of HK2 with the mitochondria and the N-terminal role in catalysis and stability of the full-length enzyme. Here, we solved the crystal structure of human HK2 in complex with glucose and glucose-6-phosphate (PDB code: 2NZT), where it is a homodimer with catalytically active N- and C-terminal domains linked by a seven-turn �?±-helix. Different from the inactive N-terminal domains of isozymes 1 and 3, the N-domain of HK2 is not only capable of catalyzing reaction but it is also responsible for thermodynamic stabilization of the full-length enzyme. Deletion of first �?±-helix of the N-domain that binds to the mitochondria altered the stability and catalytic activity of the full-length HK2. In addition, we found the linker helix between the N- and C-terminal domains to play an important role in controlling the catalytic activity of the N-terminal domain. HK2 is a major step in the regulation of glucose metabolism in cancer making it an ideal target for the development of new anticancer therapeutics. Characterizing the structural and molecular mechanisms of human HK2 and its role in cancer metabolism will accelerate the design and development of new cancer therapeutics that are safe and cancer specific.

Biography

Wael M Rabeh has received his PhD in Biochemistry from the Lab of Professor Paul F Cook, where he characterized the last enzymatic reaction of the cysteine biosynthetic pathway in Salmonella typhimurium. In 2005, he joined the Structural Genomic Consortium (SGC) at the University of Toronto as a Post-doctoral Fellow, where he characterized the 3D structure of human proteins with medical relevance using X-ray crystallography. In 2007, he joined the Lab of Dr. Gergely Lukacs at McGill University for the characterization of a membrane channel that is the main cause of cystic fibrosis. His research focuses on the characterization of protein structures and mechanism to understand their biological functions.

Email: wael.rabeh@nyu.edu